Clinical trials: Autologous Transplantation
Multiple Myeloma, Plasma Cell Neoplasm
2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00075608
- Testing
- filgrastim, melphalan, autologous stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin before autologous (taken from an individual's own cells) stem cell transplant works in treating patients with Hodgkin lymphoma.
- Trial name
- NCT01393717
- Testing
- brentuximab vedotin
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- City of Hope Medical Center
Varicella
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months…
- Trial name
- NCT00792623
- Testing
- VarilrixTM
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B Cell Non-Hodgkin Lymphoma
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
This is a single institution phase I/II study using an ADAM17 inhibitor (INCB7839) with rituximab as consolidation therapy after an autologous hematopoietic cell transplant (HCT) for patients with diffuse large B cell lymphoma…
- Trial name
- NCT02141451
- Testing
- Rituximab, INCB7839
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
For patients who receive a hematopoietic cell transplant (HCT), there is a risk of developing a diarrhea secondary to the chemotherapy which we give.
- Trial name
- NCT02619812
- Testing
- Serum-derived bovine immunoglobulin/protein isolate (SBI), Colesevelam
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Lymphoma
Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma
Primary Objectives: 1. To determine the efficacy of administering multiple doses of intravenous (i.v.) busulfan at a dose of 130 mg/m2, to yield a systemic plasma drug exposure represented by a daily area under the plasma…
- Trial name
- NCT00427765
- Testing
- Busulfan, Melphalan
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Pancreatitis, Insulin Dependent Diabetes
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for…
- Trial name
- NCT03283566
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Tinostamustine Conditioning and Autologous Stem Cell
Phase 1 The primary objectives of Phase 1 of this study are to: Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission
- Trial name
- TITANIUM1 (NCT03687125)
- Testing
- Tinostamustine, Autologous Stem Cell Transplant (ASCT)
- Where
- 12 sites in United States, Norway and 1 more
- Volunteers
- 6 people
- Sponsor
- Mundipharma-EDO GmbH
Hodgkin Lymphoma
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
- Trial name
- NCT02572167
- Testing
- brentuximab vedotin, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Seagen Inc.
Lymphoma
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
The goal of this clinical research study is to learn if ibrutinib can help to control lymphoma in patients who have had an autologous stem cell transplant (a transplant using your own stem cells).
- Trial name
- NCT02272686
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and…
- Trial name
- NCT02722941
- Testing
- Panobinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Bone Metastases
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Primary objectives: To determine the time to progression in subjects with breast cancer metastatic to bone only treated with 153Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).
- Trial name
- NCT00429507
- Testing
- 153 Sm-EDTMP, Questionnaire, Stem Cell Transplant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Stress Urinary Incontinence
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo…
- Trial name
- NCT01893138
- Testing
- Iltamiocel
- Where
- 29 sites in United States, Belgium and 1 more
- Volunteers
- 311 people
- Sponsor
- Cook MyoSite
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma.
- Trial name
- NCT01718743
- Testing
- Ixazomib Citrate, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Myasthenia Gravis
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
MG may be neonatal, congenital, or autoimmune. Neonatal MG arises from transplacental transfer of ACh receptor antibodies from a mother with autoimmune MG to the fetus.
- Trial name
- NCT00424489
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Northwestern University